"The boss of Britain's biggest pharmaceutical company has said the government's recent drug pricing deal is a very positive step but is unlikely to unfreeze a paused 200m investment in Cambridge. AstraZeneca's chief executive, Pascal Soriot, suggested that a UK-US deal on NHS pricing agreed in December would not be sufficient to restart the project to build a research site in the east of England, which was paused in September."
"Soriot, who has rebuilt the company's drugs pipeline since 2012 and turned it into the UK's most valuable listed business, also described the US as the most attractive market in the world. During Keir Starmer's visit to Beijing two weeks ago, AstraZeneca announced $15bn (11bn) of investments in China, its second-biggest market, and is also pouring $50bn into US factories and labs by 2030."
Pascal Soriot said the UK-US drug pricing deal is a very positive step but is unlikely to unfreeze a paused £200m investment in Cambridge. The December pricing agreement on NHS drugs would not be sufficient to restart the planned research site in eastern England, which was paused in September. Soriot has rebuilt AstraZeneca's drugs pipeline since 2012 and called the US the most attractive market. AstraZeneca announced $15bn of investments in China and plans $50bn for US factories and labs by 2030, while keeping its main stock listing in London.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]